Ibrahim Edhemovic

Ibrahim Edhemovic

Auto-generated profile, based on publicly available information

Ibrahim Edhemovic

Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Medicine Ljubljana, University of Ljubljana, Ljubljana, Slovenia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Annals of Surgery
Verified
Journal Article
Open access
EDEsmée A. Dijkstra
Esmée A. Dijkstra
PNPer Johan Nilsson
Per Johan Nilsson
GHGeke A.P. Hospers
Geke A.P. Hospers
RBRenu R. Bahadoer
Renu R. Bahadoer
EMElma Meershoek
Elma Meershoek
CICollaborative Investigators
Collaborative Investigators
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. Methods: A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. Results: Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P=0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P=0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P=0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P=0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46–1.26); P=0.29]. Conclusions: The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.

1 June 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MVMaxime J.M. van der Valk
Maxime J.M. van der Valk
CMCorrie A.M. Marijnen
Corrie A.M. Marijnen
BEBoudewijn van Etten
Boudewijn van Etten
EDEsmée A. Dijkstra
Esmée A. Dijkstra
DHDenise Hilling
Denise Hilling
GHGeke A.P. Hospers
Geke A.P. Hospers

1 October 2004 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
IEIbrahim Edhemovic
Ibrahim Edhemovic
WTWalley J. Temple
Walley J. Temple
CGChristopher J. de Gara
Christopher J. de Gara
GSGavin C. E. Stuart
Gavin C. E. Stuart

27 August 2015 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
BMBarbara Mali
Barbara Mali
VGVojka Gorjup
Vojka Gorjup
IEIbrahim Edhemovic
Ibrahim Edhemovic
EBErik Brecelj
Erik Brecelj
MCMaja Cemazar
Maja Cemazar
TJTomaz Jarm
Tomaz Jarm
Electrochemotherapy (ECT) is a combined treatment in which high voltage electroporation (EP) pulses are used to facilitate the uptake of a chemotherapeutic drug into tumor cells, thus increasing antitumor effectiveness of the drug. The effect of ECT of deep-seated tumors located close to the heart on functioning of the heart has not been previously investigated. In this study, we investigate the effects of intra-abdominal ECT of colorectal liver metastases on functioning of the heart during the early post-operative care period. For ECT high voltage EP pulses with amplitudes of up to 3000 V and 30 A were delivered in synchronization with electrical activity of the heart. Holter electrocardiographic (ECG) signals were obtained from 10 patients with colorectal liver metastases treated with ECT. ECG was recorded during the periods of 24 hours before and after the surgical procedure involving ECT. Four-hour long night-time ECG segments from both periods exhibiting the highest level of signal stationarity were analyzed and compared. Changes in several ECG and heart rate variability (HRV) parameters were evaluated. No major heart rhythm changes (i.e., induction of extrasystoles, ventricular tachycardia or fibrillation) or pathological morphological changes (i.e., ST segment changes) indicating myocardial ischemia were found. However, we found several minor statistically significant but clinically irrelevant changes in HRV parameters after ECT procedures: a decrease in median values of the mean NN interval, a decrease in the low-frequency and in the normalized low-frequency component, and an increase in the normalized high-frequency component. Only minor effects of intra-abdominal ECT treatment on functioning of the heart were found. They were expressed as statistically significant but clinically irrelevant changes in heart rate and long-term HRV parameters and were as such not life-threatening to the patients. The nature of these changes is such that they can be attributed to the known effects of the drugs given to the patients in the post-operative care. Further investigation is still warranted to unambiguously resolve whether ECT with high voltage EP pulses applied in immediate vicinity of the heart is responsible for the observed effects.

1 September 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
IEIbrahim Edhemovic
Ibrahim Edhemovic
EBErik Brecelj
Erik Brecelj
MCMaja Cemazar
Maja Cemazar
NBNina Boc
Nina Boc
BTBlaz Trotovsek
Blaz Trotovsek
Gregor SersaGregor Sersa
Gregor Sersa
A previous pilot study proved the feasibility, safety and efficacy of electrochemotherapy in the treatment of colorectal liver metastases. The aim of this study was to evaluate long-term effectiveness and safety of electrochemotherapy in the treatment of unresectable colorectal liver metastases. In this prospective phase II study, patients with metachronous colorectal liver metastases were included. In all patients, at least one metastasis was unresectable due to its central location or a too-small future remnant liver volume. Patients were treated by electrochemotherapy using intravenously administered bleomycin during open surgery. Treated were 84 metastases in 39 patients. Local tumor control, progression-free survival and overall survival were evaluated. The objective response was 75% (63% CR, 12% PR). The median duration of the response was 20.8 months for metastases in CR and 9.8 months for metastases in PR. The therapy was significantly more effective for metastases smaller than 3 cm in diameter than for larger ones. There was no difference in response according to the metastatic location, i.e., metastases in central vs. peripheral locations. Progression-free survival was better in patients who responded well to electrochemotherapy compared to those metastases that had a partial response or progressive disease. However, there was no difference in overall survival, with a median of 29.0 months. Electrochemotherapy has proven to be safe and effective in the treatment of colorectal liver metastases, with a durable response. It provides local tumor control that enables patients with unresectable metastases to receive further treatments.

1 November 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
JHJos van der Hage
Jos van der Hage
SSsergio Sandrucci
sergio Sandrucci
RARiccardo Audisio
Riccardo Audisio
LWLynda Wyld
Lynda Wyld
TATeresa F Amaral
Teresa F Amaral
AEAne Gerda Zahl Eriksson
Ane Gerda Zahl Eriksson
Surgical oncology is a defined specialty within the European Board of Surgery within the European Union of Medical Specialists (UEMS). Variation in training and specialization still occurs across Europe. There is a need to align the core knowledge needed to fulfil the criteria across subspecialities in surgical oncology. The core curriculum, established in 2013, was developed with contributions from expert advisors from within the European Society of Surgical Oncology (ESSO), European Society for Radiotherapy and Oncology (ESTRO) and European Society of Medical Oncology (ESMO) and related subspeciality experts. The current version reiterates and updates the core curriculum structure needed for current and future candidates who plans to train for and eventually sit the European fellowship exam for the European Board of Surgery in Surgical Oncology. The content included is not intended to be exhaustive but, rather to give the candidate an idea of expectations and areas for in depth study, in addition to the practical requirements. The five elements included are: Basic principles of oncology; Disease site specific oncology; Generic clinical skills; Training recommendations, and, lastly; Eligibility for the EBSQ exam in Surgical Oncology. As evidence-based care for cancer patients evolves through research into basic science, translational research and clinical trials, the core curriculum will evolve, mature and adapt to deliver continual improvements in cancer outcomes for patients.